Trial
NCT05450562
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Neoplasm
Intervention
SAR444200
Why stopped
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-14